Sodium oxybate controlled release - Tris pharma
Alternative Names: TRN-257Latest Information Update: 15 Jun 2026
At a glance
- Originator Tris Pharma
- Class Butyric acids; Hydroxybutyrates; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Yes - Idiopathic hypersomnia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Idiopathic hypersomnia; Narcolepsy
Highest Development Phases
- Preregistration Idiopathic hypersomnia; Narcolepsy
Most Recent Events
- 15 Jun 2026 Sodium oxybate controlled release - Tris pharma receives Orphan Drug status for Idiopathic hypersomnia in USA
- 10 Jun 2026 Sodium oxybate controlled release - Tris pharma is available for licensing in World as of 10 Jun 2026. https://www.trispharma.com/
- 09 Dec 2025 Preregistration for Idiopathic hypersomnia (In adults) in USA (PO) before December 2025